Canada's Biotech Challenge
The desk views Canada's biotech sector as facing significant challenges regarding talent and ownership retention, particularly as AI and competition from countries like China reshape drug discovery methodologies. Per the full note from RBC Royal Bank, while Canadian medical research is thriving, many successful ventures ultimately relocate abroad, impacting national economic interests and innovation capacity. This context frames potential risks for Canadian assets as global competition intensifies. Additionally, the focus on domestic industry support may build on trends emphasized by various Canadian enterprises enhancing innovation ecosystems.
What the desk is arguing
The desk highlights a pressing challenge for Canada's biotech landscape: despite notable advancements in medical research, many innovative companies relocate due to lack of local scaling opportunities. Per the full note from RBC Royal Bank, the exodus of talent, revenue, and ownership undermines Canada's potential to build an enduring industry base.
The conversation with Clarissa Desjardins emphasizes that Canada must foster an environment supportive of local scaling for biotech firms to thrive in a competitive global arena. Data indicates that over the past decade, Canadian biotech firms have consistently lagged behind their American counterparts in terms of growth and capital investment, which speaks to the urgency of strategic interventions.
Where it sits in our coverage
The desk is aligned with a consensus target of 1.075 for USD/CAD, where the outlook reflects broader economic conditions influenced by factors like trade dynamics and energy prices. Notably, targeted forecasts from other firms include: - JPMorgan: 1.10 (Mar-26) - BofA: 1.04 (Mar-26)
This analysis positions the desk's view at the mid-range of the current spectrum, with room for potential upward adjustments should domestic innovations stabilize the investment landscape.
How other firms see it
Several aligned firms, such as jpmorgan, project a bullish sentiment that resonates with our desk's cautious optimism toward the domestic market. In contrast, bofa maintains a more cautious stance, citing global economic uncertainty as a pivotal factor affecting the CAD outlook.
Market correlation effects may manifest in pairs like EUR/CAD, influenced by broader Eurozone economic indicators and their subsequent impact on commodity prices. Additionally, trends in USD/CAD could reflect shifts resulting from changes in investment sentiment towards Canadian assets, especially in biotech.
What the calendar says
There are no high-impact events scheduled for the next 30 days that could directly influence the CAD or offer immediate catalysts for shifts in the biotech sector dynamics.
How firms align with this view
Aligned with the desk view
Contrary positioning
Key takeaways
- 01Canada's biotech sector is challenged by talent outflow and competitive relocation.
- 02Domestic scaling opportunities are essential for fostering innovation and economic growth.
- 03Expert insights underscore the need for strategic interventions to retain biotech companies.
- 04Market forecasts suggest room for upward adjustments based on investment landscape stability.
Market implications
Traders should monitor USD/CAD around the 1.075 level, particularly while observing domestic policy responses to support local biotech initiatives. A failure to stimulate necessary growth could have ramifications beyond the currency, impacting broader asset allocations toward Canadian equities.
Risks to this view
A shift in U.S. policy fostering increased competition in biotech or enhanced tax incentives for relocation could undermine Canada's efforts in retaining industry talent and firms. Furthermore, any sustained downturn in the global markets that impacts investor confidence could negatively affect domestic biotech funding.
RBC Royal Bank View Online Dear Brian Canadian medical research has produced breakthrough after breakthrough. But too often, the companies behind the science scale elsewhere, and the talent, revenue and ownership goes, too. On the latest episode of Disruptors, Clarissa Desjardins, co-founder and CEO of Montreal’s Congruence Therapeutics, talks with host John Stackhouse about what it will take to change that, all while AI and China reshape drug discovery.
Listen to Disruptors We encourage you to share this message with your network and ask them to join our mailing list to get in-depth research on the big ideas that can drive Canada’s economic prosperity. - Please do not respond to this email as this inbox is not monitored. You received this email because you subscribed to RBC Thought Leadership. If you no longer wish to receive these emails, you can unsubscribe using the link below.
Privacy & Security | Legal | Unsubscribe - RBC Royal Bank | Royal Bank of Canada 200 Bay Street, South Tower, 9th Floor, Toronto, ON M5J 2J2, Canada | rbc.com/thoughtleadership (R)/TM Trademark(s) of Royal Bank of Canada. RBC and Royal Bank are registered trademarks of Royal Bank of Canada (c) Royal Bank of Canada 2026
Sources & References
How we cover this story